Why I’m avoiding these 3 FTSE 100 stocks in 2020

G A Chester sees different issues with these three FTSE 100 (INDEXFTSE:UKX) stocks, but valuations are the acid test.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are a number of FTSE 100 stocks I think could disappoint investors in 2020. Among them are AstraZeneca (LSE: AZN), St. James’s Place (LSE: STJ) and Scottish Mortgage Investment Trust (LSE: SMT). Here’s why I’m avoiding these three.

Dubious core strength

AstraZeneca’s management has maintained the core earnings per share (EPS) guidance it gave at the start of the year of $3.50-$3.70 for 2019. At the midpoint and current exchange rates, this gives a price-to-earnings (P/E) ratio of 26.5 at a share price of 7,300p.

This is a huge premium to Footsie pharma peers GlaxoSmithKline and Hikma Pharmaceuticals, which trade at P/Es of 14.4 and 17.7 respectively. Furthermore, I’d argue AZN’s core EPS, on which the 26.5 P/E is based, grossly overstates its real core earnings, and that the true P/E is nearer a jaw-dropping 40.

This is because I exclude one-off profits from the divestment of non-core assets, which can’t go on forever but which AZN books as core operating profit. I also include legal costs (a routine expense in operating a big pharma company), which AZN excludes. AZN looks overvalued to me on its own core EPS measure, but grossly overvalued on what I consider its true core earnings.

Iffy business model

I’m avoiding wealth manager St. James’s Place on a view that it’s not only overvalued, but also has an iffy business model, and will have to change, with profit-margin-sapping consequences.

At a share price of around 1,100p, STJ’s P/E is 32.4 on forecast EPS of 34p for 2019. This earnings multiple is far too high, in my opinion. Furthermore, a valuation of more than 3% of funds under management (FUM) has proved a trusty indicator of overvaluation, in my experience. With a market capitalisation of £5.88bn, and FUM of £112.82bn, STJ is valued at 5.2% of FUM.

The company’s management fees and exit fees are excessive, in my view. Investors haven’t worried too much about this, seeing their portfolios increase in value over the last 10 years of rising markets, but are likely to pay a lot more attention in a downturn. Furthermore, with investors generally becoming a lot savvier about the corrosive effect of fees on returns, I think STJ will ultimately have to reset its margins.

Bonkers

It’s a peculiar and persistent feature of the UK stock market that some investment trust or another will rise from the FTSE 250 to the FTSE 100. However, no trust in history has gained sufficient critical mass to maintain its position in the top index.

Scottish Mortgage is the current representative in the FTSE 100. It’s achieved its status by a combination of high returns (471% over the last 10 years) and increasing popularity with investors (taking its shares to a premium to net asset value (NAV)).

The company has surfed on the outperformance of the US market and tech sector, holding a number of the so-called FAANG stocks, and the likes of Illumina and Tesla. The managers of the trust have borrowed money to gear returns (gearing is currently 9%), and remain optimistic on the outlook.

Personally, I think the valuations of many of the underlying holdings are bonkers. I fear a de-rating, SMT’s NAV dropping, gearing working negatively, and the shares moving to a wide discount to NAV. If so, SMT will become another in the long history of investment trusts failing to maintain a place in the FTSE 100.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline and Tesla. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A pastel colored growing graph with rising rocket.
Investing Articles

£10,000 of shares in this FTSE 100 dividend superstar can make me a £16,060 annual passive income!

This FTSE 100 gem appears set for strong growth, looks undervalued to me, and pays a 9%+ dividend yield that…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

No savings? I’d start off an empty ISA by considering these 2 dirt cheap dividend shares

Despite a resurgent UK stock market, its possible to find cheap-looking dividend shares, such as these that I’d consider now.

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

Down 53% in a year! I reckon this oversold FTSE 100 stock is now ripe for a comeback

This FTSE 100 stock has fallen out of fashion with investors, but Harvey Jones reckons the sell-off has gone too…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

How much second income would I get if I put £10k into dirt cheap Centrica shares?

Centric shares have been looking incredibly cheap despite rocketing in recent years. Harvey Jones wonders whether this is an opportunity…

Read more »

artificial intelligence investing algorithms
Investing Articles

If I’d invested £10k in AstraZeneca shares three months ago here’s what I’d have now

Harvey Jones is kicking himself for failing to buy AstraZeneca shares before the took off. Is there still a decent…

Read more »

A senior group of friends enjoying rowing on the River Derwent
Investing Articles

How I’d find shares to buy for an early retirement

Christopher Ruane explains some of the factors he considers when looking for shares to buy that could potentially help him…

Read more »

Investing Articles

Why I’d snap up bargain UK shares to try and build wealth

Christopher Ruane explains how he hopes to find high-quality UK shares selling at attractive prices, to help him build wealth…

Read more »

Young Caucasian woman at the street withdrawing money at the ATM
Investing Articles

Here’s how I’d target a £2k annual second income from a £20k Stocks & Shares ISA

Our writer explains how he’d try to earn thousands of pounds annually in dividends by investing a £20k ISA in…

Read more »